Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii

Medical Mycology

Volumn 48, Issue 2, 2010, Pages 255-262

  Vu, Kiem ^a   Gelli, Angie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Astemizole; Cryptococcus neoformans; Drug; Fluconazole; Fungicidal

Indexed keywords

1H BENZIMIDAZOLE 2 AMINE,1 [2 (4 METHOXYPHENYL)ETHYL] N [1 [2 (4 METHOXYPHENYL)ETHYL] 4 PIPERIDINYL]; 1H BENZIMIDAZOLE 2 AMINE,N [(4 METHOXYPHENYL)METHYL] 1 [2 (1 PIPERIDINYL)ETHYL]; 4 PIPERIDINAMINE N [1 [(4 FLUOROPHENYL)METHYL] 1H BENZIMIDAZOL 2 YL] 1 [(4METHOXYPHENYL)ACETYL]; ANTIFUNGAL AGENT; ASTEMIZOLE; FLUCONAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL RESISTANCE; ANTIMALARIAL ACTIVITY; ARTICLE; CATERPILLAR; CONTROLLED STUDY; CRYPTOCOCCUS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DISK DIFFUSION; DRUG POTENTIATION; FUNGICIDAL ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; SINGLE DRUG DOSE; SURVIVAL;

CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS VAR. GRUBII; FILOBASIDIELLA NEOFORMANS; GALLERIA MELLONELLA; LEPIDOPTERA;

EID: 76649137973     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903081968     Document Type: Article

References (25)

1. Martin CA. Invasive fungal infections in the critically ill patient. J Pharm Prac 2005; 18: 9-17.
2. Eisenman HC, Casadevall A, McClelland EE. New insights on the pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect Dis Reports 2007; 9: 457-464.
3. Chaayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2006; 20: 507-544.
4. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693-715.
5. Bicanic T, Harrison TS. Cryptococcal meningitis. British Med Bulletin 2004; 72: 99-118.
6. Aller AI, Martin-Mazuelos E, Lozano F, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000; 44: 1544-1548.
7. Kauffman CA. Clinical efficacy of new antifungal agents. Curr Opin Microbiol 2006; 9: 483-488.
8. Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanism of action. Trends in Microbiol 2003; 11: 272-279.
9. Xu J, Onyewu C, Yoell HJ, et al. Dynamic and heterogenous mutations to fluconazole resistance in Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45: 420-427.
10. Onyewu C, Blankenship JR, Del Poeta M, Heitman J. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata and Candida krusei. Antimicrob Agents Chemother 2003; 47: 956-964.
11. Marchetti O, Entenza JM, Sanglard D, et al. Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother 2000; 44: 2932-2938.
12. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006; 8: 415-416.
13. Fischer MJE, Paulussen JJC, Horbach DA, e t al. Inhibition of mediator release in RBL-2H3 cells by some H 1 -antagonist derived anti-allergic drugs: relation to lipophilicity and membrane effects. Inflamm Res 1995; 44: 92-97.
14. Chamilos GMS, Lionakis ER, Lewis E, Kontoyiannis DP. Role of mini-host models in the study of medically important fungi. Lancet Infect Dis 2007; 7: 42-55.
15. Myloakis ER, Moreno JB, Khoury EL, et al. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun 2005; 73: 3842-3850.
16. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards. Reference method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard- Second Edition, M27-A2, 940 West Valley Road, Suite 1400, Wayne, PA. pp. 19087-21898 USA, 2004.
17. Taglialatela M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 2000; 21: 52-56.
18. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus ooctyes by the histamine receptor antagonist terfenadine and astemizole. FEBS Lett 1996; 385: 77-80.
19. + channel, IKCa1: a potential immunosuppressant. PNAS 97: 8151-8156.
20. Hong Nguyen M, Barchiesi F, McGough DA, Yu VL, Rinaldi MG. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother 1995; 39: 1691-1695.
21. Barchiesi F, Gallo D, Caselli F, et al. In vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother 1999; 44: 65-70.
22. Allendoerfer R, Marquis AJ, Rinaldi MG, Graybill JR. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother 1991; 35: 726-729.
23. Nucci M, Perfect JR. When primary antifungal therapy fails. C lin Infect Dis 2008; 46: 1426-1433.
24. Cuenca-Estrella M. Combinations of antifungal agents in therapy - what value are they? J Antimicrob Chemother 2004; 54: 854-869.
25. Pasqualotto AC, Denning D. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008; 61: ( Suppl. 1 ): i19- 130.